Fruquintinib (FRUZAQLA™) is a VEGFR-1/2/3 inhibitor used in cancer treatment. In two phase 1 studies supported by AMR Clinical sites, researchers assessed its pharmacokinetics in participants with moderate hepatic or moderate to severe renal impairment. Fruquintinib exposure was comparable to that in healthy controls, and the drug was well tolerated across groups. The findings support fruquintinib use without dose adjustment in these patient populations.
Read this publication to explore:
- PK comparisons by impairment type vs matched controls
- Dose levels studied and key exposure parameters (Cmax, AUC)
- Tolerability outcomes and dosing recommendations